Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
A phase 1/2 trial of Osimertinib, Pemetrexed, Carboplatin in mesothelioma, run by Vivace Therapeutics, Inc, now recruiting.
Overview
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT04665206 by Vivace Therapeutics, Inc, with 434 participants planned, started 2021-03-24 and due to reach its primary completion in 2029-11-02. Interventions recorded: VT3989, Nivolumab & Ipilimumab, Osimertinib, Pemetrexed/Carboplatin. Conditions listed: Solid Tumor, Adult, Mesothelioma, NSCLC. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialTo Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
Shares Osimertinib, Pemetrexed, Carboplatin.
- TrialA Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Shares Pemetrexed, Carboplatin.
- TrialA Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S
Shares Osimertinib, Pemetrexed, Carboplatin.
- TrialMEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
Shares Mesothelioma, Pemetrexed, Carboplatin.
- TrialSavolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Shares Osimertinib, Pemetrexed, Carboplatin.
- TrialStudy of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Shares Pemetrexed, Carboplatin.
- TrialStudy of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
Shares Pemetrexed, Carboplatin.
- TrialA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participan
Shares Osimertinib, Pemetrexed, Carboplatin.